Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction.

AIM The interindividual variability in the dose required for effective methadone maintenance treatment (MMT) for opioid addiction may be influenced in part by genetic variations in genes encoding pharmacodynamic factors of methadone. This study was conducted to identify some of these variants. MATERIALS & METHODS This study focused on 11 genes encoding components of the opioidergic (OPRM1, POMC and ARRB2), the dopaminergic (ANKK1 and DRD2) and the glutamatergic pathways (GRIN1 and GRIN2A), as well as the neurotrophin system (NGFB, BDNF, NTRK1 and NTRK2). The study includes 227 Israeli patients undergoing stable MMT. RESULTS Out of the 110 variants analyzed, 12 SNPs (in BDNF, NTRK2, OPRM1, DRD2 and ANKK1) were associated with methadone dose (nominal p < 0.05). Of these SNPs, ANKK1 rs7118900 and DRD2 rs2283265 are known to affect gene expression. Logistic regression of five representative SNPs discriminated between individuals requiring a methadone dose of >120 mg/day and <120 mg/day (p = 0.019), and showed moderate sensitivity and specificity (AUC of 0.63 in receiver operating characteristic analysis). CONCLUSION This data should stimulate further research on the potential influence and clinical significance of these variants on MMT.

[1]  O. Levran,et al.  CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction , 2013, Addiction biology.

[2]  David Borsook,et al.  Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges. , 2013, The journal of pain : official journal of the American Pain Society.

[3]  E. Nestler,et al.  BDNF Is a Negative Modulator of Morphine Action , 2012, Science.

[4]  O. Levran,et al.  The genetics of the opioid system and specific drug addictions , 2012, Human Genetics.

[5]  A. Somogyi,et al.  ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics , 2012, Pharmacogenomics and personalized medicine.

[6]  C. Wahlestedt,et al.  Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation , 2012, Nature Biotechnology.

[7]  E. Palazidou.  The neurobiology of depression. , 2012, British medical bulletin.

[8]  L. Santy,et al.  CNK3 and IPCEF1 produce a single protein that is required for HGF dependent Arf6 activation and migration. , 2012, Experimental cell research.

[9]  A. Serretti,et al.  Influence of BDNF Variants on Diagnosis and Response to Treatment in Patients with Major Depression, Bipolar Disorder and Schizophrenia , 2011, Neuropsychobiology.

[10]  H. Lane,et al.  Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. , 2011, Pharmacogenomics.

[11]  H. Zhen,et al.  The brain-derived neurotrophic factor is associated with alcohol dependence-related depression and antidepressant response , 2011, Brain Research.

[12]  X. Miao,et al.  Association between polymorphisms of DRD2 and DRD4 and opioid dependence: Evidence from the current studies , 2011, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[13]  R. Lefkowitz,et al.  Emerging paradigms of β-arrestin-dependent seven transmembrane receptor signaling. , 2011, Trends in biochemical sciences.

[14]  M. Preisig,et al.  β-Arrestin2 influences the response to methadone in opioid-dependent patients , 2011, The Pharmacogenomics Journal.

[15]  Yaqin Yu,et al.  Susceptibility genes, social environmental risk factors and their interactions in internalizing disorders among mainland Chinese undergraduates. , 2011, Journal of affective disorders.

[16]  Binbin Wang,et al.  Genetic association between BDNF gene polymorphisms and phobic disorders: a case-control study among mainland Han Chinese. , 2011, Journal of affective disorders.

[17]  J. Hoenicka,et al.  The ANKK1 Protein Associated with Addictions has Nuclear and Cytoplasmic Localization and Shows a Differential Response of Ala239Thr to Apomorphine , 2011, Neurotoxicity Research.

[18]  Shih-Chieh Chang,et al.  Images in clinical medicine. Acute mesenteric infarction associated with atrial fibrillation. , 2011, The New England journal of medicine.

[19]  Richard M Weinshilboum,et al.  Genomics and drug response. , 2011, The New England journal of medicine.

[20]  Wolfgang Sadee,et al.  Intronic Polymorphisms Affecting Alternative Splicing of Human Dopamine D2 Receptor Are Associated with Cocaine Abuse , 2011, Neuropsychopharmacology.

[21]  Bin Zhang,et al.  Nerve growth factor beta polypeptide (NGFB) genetic variability: association with the methadone dose required for effective maintenance treatment , 2011, The Pharmacogenomics Journal.

[22]  Y. Lecrubier,et al.  Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder , 2011, International clinical psychopharmacology.

[23]  M. Gill,et al.  Increased BDNF levels and NTRK2 gene association suggest a disruption of BDNF/TrkB signaling in autism , 2010, Genes, brain, and behavior.

[24]  Saharon Rosset,et al.  The genome-wide structure of the Jewish people , 2010, Nature.

[25]  Itsik Pe'er,et al.  Abraham's children in the genome era: major Jewish diaspora populations comprise distinct genetic clusters with shared Middle Eastern Ancestry. , 2010, American journal of human genetics.

[26]  S. Mague,et al.  OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. , 2010, Drug and alcohol dependence.

[27]  M. Kreek,et al.  Pharmacotherapy in the Treatment of Addiction: Methadone , 2010, Journal of addictive diseases.

[28]  Kerang Zhang,et al.  Genetic association of the interaction between the BDNF and GSK3B genes and major depressive disorder in a Chinese population , 2010, Journal of Neural Transmission.

[29]  G. Glover,et al.  A Genetic Variant BDNF Polymorphism Alters Extinction Learning in Both Mouse and Human , 2010, Science.

[30]  G. Pasternak.  Molecular Insights Into μ Opioid Pharmacology: From the Clinic to the Bench , 2010, The Clinical journal of pain.

[31]  J. Hoenicka,et al.  The ANKK1 Gene Associated with Addictions Is Expressed in Astroglial Cells and Upregulated by Apomorphine , 2010, Biological Psychiatry.

[32]  R. Plomin,et al.  Common disorders are quantitative traits , 2009, Nature Reviews Genetics.

[33]  J. Licinio,et al.  Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans , 2009, Molecular Psychiatry.

[34]  M. Gratacós,et al.  A Brain-Derived Neurotrophic Factor Haplotype Is Associated with Therapeutic Response in Obsessive-Compulsive Disorder , 2009, Biological Psychiatry.

[35]  J. McGough,et al.  Estimating the size of treatment effects: moving beyond p values. , 2009, Psychiatry (Edgmont (Pa. : Township)).

[36]  K. Befort,et al.  Reward processing by the opioid system in the brain. , 2009, Physiological reviews.

[37]  Nicole P. Yuan,et al.  Association of substance use disorders with childhood trauma but not African genetic heritage in an African American cohort. , 2009, The American journal of psychiatry.

[38]  Annette Lee,et al.  European Population Genetic Substructure: Further Definition of Ancestry Informative Markers for Distinguishing among Diverse European Ethnic Groups , 2009, Molecular medicine.

[39]  M. Rietschel,et al.  Genetic Predictors of Increase in Suicidal Ideation During Antidepressant Treatment in the GENDEP Project , 2009, Neuropsychopharmacology.

[40]  R. Sinha.  Stress and Addiction: A Dynamic Interplay of Genes, Environment, and Drug Intake , 2009, Biological Psychiatry.

[41]  J. Ott,et al.  Heroin addiction in African Americans: a hypothesis‐driven association study , 2009, Genes, brain, and behavior.

[42]  A. Doehring,et al.  Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution , 2009, Pharmacogenetics and genomics.

[43]  Pardis C Sabeti,et al.  Population genetic study of the brain-derived neurotrophic factor (BDNF) gene , 2009, Molecular Psychiatry.

[44]  Leonardo Fazio,et al.  Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. , 2009, Brain : a journal of neurology.

[45]  Aleksey Y. Ogurtsov,et al.  Expansion of the human μ-opioid receptor gene architecture: novel functional variants , 2008, Human molecular genetics.

[46]  F. McMahon,et al.  Evidence of association between brain-derived neurotrophic factor gene and bipolar disorder , 2008, Psychiatric genetics.

[47]  R. Barrack,et al.  Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients , 2008, Journal of thrombosis and haemostasis : JTH.

[48]  M. Preisig,et al.  Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[49]  J. Ott,et al.  Genetic susceptibility to heroin addiction: a candidate gene association study , 2008, Genes, brain, and behavior.

[50]  David Goldman,et al.  Addictions biology: haplotype-based analysis for 130 candidate genes on a single array. , 2008, Alcohol and alcoholism.

[51]  S. Kaasa,et al.  Clinical pharmacology of methadone for pain , 2008, Acta anaesthesiologica Scandinavica.

[52]  J. Ott,et al.  ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. , 2008, Human molecular genetics.

[53]  M. Gratacós,et al.  BDNF variability in opioid addicts and response to methadone treatment: preliminary findings , 2008, Genes, brain, and behavior.

[54]  R. Perry,et al.  Genetic Association of Neurotrophic Tyrosine Kinase Receptor Type 2 (NTRK2) With Alzheimer's Disease , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[55]  M. Gratacós,et al.  A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders , 2008, The Pharmacogenomics Journal.

[56]  J. González,et al.  Extensive Genotyping of the BDNF and NTRK2 Genes Define Protective Haplotypes Against Obsessive-Compulsive Disorder , 2008, Biological Psychiatry.

[57]  Leonardo Fazio,et al.  Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory , 2007, Proceedings of the National Academy of Sciences.

[58]  Hongyu Zhao,et al.  Association of haplotypic variants in DRD2, ANKK1, TTC12 and NCAM1 to alcohol dependence in independent case control and family samples. , 2007, Human molecular genetics.

[59]  M. Gratacós,et al.  Altered brain‐derived neurotrophic factor blood levels and gene variability are associated with anorexia and bulimia , 2007, Genes, brain, and behavior.

[60]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[61]  M. Kreek,et al.  Correlation Between High Methadone Doses and Methadone Serum Levels in Methadone Maintenance Treatment (MMT) Patients , 2007, Journal of addictive diseases.

[62]  Robert Lipsky,et al.  Nucleotide sequence variation within the human tyrosine kinase B neurotrophin receptor gene: association with antisocial alcohol dependence , 2007, The Pharmacogenomics Journal.

[63]  Ming D. Li,et al.  Association of Specific Haplotypes of Neurotrophic Tyrosine Kinase Receptor 2 Gene (NTRK2) with Vulnerability to Nicotine Dependence in African-Americans and European-Americans , 2007, Biological Psychiatry.

[64]  K. Brady,et al.  Haplotype spanning TTC12 and ANKK1, flanked by the DRD2 and NCAM1 loci, is strongly associated to nicotine dependence in two distinct American populations. , 2006, Human molecular genetics.

[65]  David Goldman,et al.  Using ancestry-informative markers to define populations and detect population stratification , 2006, Journal of psychopharmacology.

[66]  A. Somogyi,et al.  Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments , 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[67]  R. Hashimoto,et al.  A complex polymorphic region in the brain-derived neurotrophic factor (BDNF) gene confers susceptibility to bipolar disorder and affects transcriptional activity , 2006, Molecular Psychiatry.

[68]  G. Pasternak,et al.  Identification and characterization of six new alternatively spliced variants of the human μ opioid receptor gene, Oprm , 2005, Neuroscience.

[69]  Ming D. Li,et al.  Significant association of BDNF haplotypes in European‐American male smokers but not in European‐American female or African‐American smokers , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[70]  S. Tsai,et al.  Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males. , 2005, Brain research. Molecular brain research.

[71]  David Michelson,et al.  Efficacy of atomoxetine in adult attention-Deficit/Hyperactivity Disorder: a drug-placebo response curve analysis , 2005, Behavioral and Brain Functions.

[72]  Mariza de Andrade,et al.  Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson's Disease , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[73]  M. Kreek,et al.  Pharmacogenetics and Human Molecular Genetics of Opiate and Cocaine Addictions and Their Treatments , 2005, Pharmacological Reviews.

[74]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[75]  Daniele Lecca,et al.  Dopamine and drug addiction: the nucleus accumbens shell connection , 2004, Neuropharmacology.

[76]  Marc G Caron,et al.  Desensitization of G protein-coupled receptors and neuronal functions. , 2004, Annual review of neuroscience.

[77]  M. Neville,et al.  Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1 , 2004, Human mutation.

[78]  C. Yost,et al.  Functional Inhibition by Methadone of N-Methyl-d-Aspartate Receptors Expressed in Xenopus Oocytes: Stereospecific and Subunit Effects , 2004, Anesthesia and analgesia.

[79]  M. Egan,et al.  The BDNF val66met Polymorphism Affects Activity-Dependent Secretion of BDNF and Human Memory and Hippocampal Function , 2003, Cell.

[80]  P. Muglia,et al.  The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. , 2002, American journal of human genetics.

[81]  D. Naiman,et al.  Polysubstance abuse-vulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms. , 2001, American journal of human genetics.

[82]  Alessandro Usiello,et al.  Distinct functions of the two isoforms of dopamine D2 receptors , 2000, Nature.

[83]  E P Noble,et al.  The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. , 2000, American journal of medical genetics.

[84]  M. Kreek,et al.  Methadone‐Related Opioid Agonist Pharmacotherapy for Heroin Addiction: History, Recent Molecular and Neurochemical Research and Future in Mainstream Medicine , 2000, Annals of the New York Academy of Sciences.

[85]  R. Gainetdinov,et al.  Enhanced morphine analgesia in mice lacking beta-arrestin 2. , 1999, Science.

[86]  J A Tischfield,et al.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[87]  A. Gorman,et al.  The d- and l- isomers of methadone bind to the non-competitive site on the N-methyl-d-aspartate (NMDA) receptor in rat forebrain and spinal cord , 1997, Neuroscience Letters.

[88]  E. Noble.  The D2 dopamine receptor gene: A review of association studies in alcoholism , 1993, Behavior genetics.

[89]  G. Di Chiara,et al.  Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[90]  C. Metz.  Basic principles of ROC analysis. , 1978, Seminars in nuclear medicine.

[91]  Michael C. Hout,et al.  Multidimensional Scaling , 2003, Encyclopedic Dictionary of Archaeology.

[92]  L. Monteggia,et al.  Brain-derived neurotrophic factor and neuropsychiatric disorders. , 2012, Pharmacological reviews.

[93]  K. Malone,et al.  Risk and protective genetic variants in suicidal behaviour: association with SLC1A2, SLC1A3, 5-HTR1B & NTRK2 polymorphisms , 2011 .

[94]  Marie-H Monfils,et al.  Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity. , 2010, Current molecular pharmacology.

[95]  S. Gabriel,et al.  Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus , 2002, Molecular Psychiatry.

[96]  S Rozen,et al.  Primer3 on the WWW for general users and for biologist programmers. , 2000, Methods in molecular biology.

[97]  R. Spitzer,et al.  Using signal detection methodology to revise DSM-III-R: re-analysis of the DSM-III-R national field trials for autistic disorder. , 1990, Journal of psychiatric research.